Inhibikase Therapeutics awards stock options to CEO and CFO with performance vesting tied to Phase 2a study

Inhibikase Therapeutics, Inc.

CEO Milton H. Werner granted options for 315,000 shares at $0.7390; 105,000 subject to performance vesting.
CFO Joseph Frattaroli granted options for 135,000 shares at $0.7390; 45,000 subject to performance vesting.
Performance milestones tied to completion and release of IKT-148009 Phase 2a study in Parkinson's disease.
Remaining options subject to time vesting under 2020 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.